Blood Biomarker Disclosure Doubles Alzheimer Diagnostic Certainty in Randomized Trial
Sharing p-tau217 and NfL results early boosted high-confidence Alzheimer diagnoses from 4.6% to 50% without worsening patient anxiety.
Summary
A randomized trial at a Spanish memory clinic tested whether revealing blood-based Alzheimer biomarkers — specifically plasma phosphorylated tau 217 (p-tau217) and neurofilament light chain (NfL) — earlier in the diagnostic process improves outcomes. Among 220 patients with subjective cognitive decline, mild cognitive impairment, or mild dementia, those who received their results at 3 months were dramatically more likely to achieve a high-confidence etiologic diagnosis than those who waited until 9 months (50% vs. 4.6%). Earlier disclosure also led to more patients starting Alzheimer treatment sooner, fewer unnecessary follow-up neuropsychological tests, and more appropriate referrals back to primary care. Critically, receiving results early did not increase anxiety, depression, or perceived stress. The findings make a strong case for integrating blood-based biomarkers into routine memory clinic evaluations.
Detailed Summary
Alzheimer's disease diagnosis has long depended on expensive, invasive, or delayed testing — lumbar punctures for cerebrospinal fluid, PET imaging, or years of clinical observation. The emergence of accurate, affordable blood-based biomarkers like p-tau217 and NfL promises to change this, but rigorous evidence that earlier disclosure actually benefits patients in routine clinical practice has been lacking. This trial directly addresses that gap.
Researchers at Hospital del Mar in Barcelona randomized 220 consecutive memory clinic outpatients to receive their p-tau217 and NfL results at either 3 months (earlier disclosure) or 9 months (delayed disclosure) after enrollment. Participants had diagnoses of subjective cognitive decline (46%), mild cognitive impairment (31%), or mild dementia (24%), with a median age of 73 years and 56% women.
The results were striking. At the 3-month mark, 50% of patients in the earlier-disclosure group had achieved a very high-confidence etiologic diagnosis (≥90% certainty), compared with just 4.6% in the delayed group. Earlier disclosure also nearly tripled the rate of symptomatic Alzheimer treatment initiation (14.3% vs. 4.6%), cut unnecessary neuropsychological reassessments nearly in half (30% vs. 53%), and more than doubled appropriate discharge to primary care (31% vs. 12%). For patients with mild cognitive impairment specifically, the diagnostic certainty advantage persisted even after the delayed group eventually received their results.
Perhaps most reassuring for clinicians hesitant to share potentially distressing biological findings: earlier disclosure showed no negative impact on anxiety, depression, perceived stress, or quality of life across follow-up.
The implications for clinical practice are significant. Blood biomarkers could streamline memory clinic workflows, reduce diagnostic limbo, and accelerate access to emerging Alzheimer therapies — particularly relevant as disease-modifying treatments become available. Caveats include single-center design and abstract-only access for this summary.
Key Findings
- Earlier p-tau217/NfL disclosure raised high-confidence Alzheimer diagnoses from 4.6% to 50% at 3 months.
- Symptomatic Alzheimer treatment was initiated 3x more often with early biomarker disclosure (14.3% vs. 4.6%).
- Unnecessary neuropsychological follow-up visits fell by 22 percentage points with earlier disclosure.
- Earlier disclosure did not worsen anxiety, depression, perceived stress, or quality of life.
- Diagnostic certainty advantage persisted long-term in the MCI subgroup even after delayed disclosure.
Methodology
Prospective randomized clinical trial (NCT06246019) conducted at a single memory clinic in Barcelona between February and October 2024, with 9 months of follow-up. Of 265 eligible consecutive outpatients with SCD, MCI, or mild dementia, 220 were randomized 1:1 to earlier (3-month) or delayed (9-month) disclosure of plasma p-tau217 and NfL results alongside standard clinical evaluation.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access. The trial was conducted at a single center in Spain, which may limit generalizability to other healthcare settings. The 9-month follow-up period may be insufficient to assess longer-term emotional or clinical management outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: